BTIG Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $810

Benzinga Newsdesk www.benzinga.com Negative 62.0%

Neg 62% Neu 0% Pos 0%

BTIG analyst Kambiz Yazdi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $843 to $810.